Active Not RecruitingNCT05711940

Two COMP360 doses for treatment-resistant depression

About this title

Read the official source —

Medication studyAges 18+Multiple countries

The study in practice

Understand this study

Who could participate?

This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.

Listed locations: Gilbert and 115 more locationsSee all locations and recruitment
Study phase: Phase 3

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: February 14, 2023

Recruitment status: Active Not Recruiting
Enrollment listed in the registry: 572
Sponsor: COMPASS Pathways
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: United States, France, Canada, ...
Age range: Over 18 Years
Official registry ID: NCT05711940
Official title: Show the full official title
A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression

Get this study by email

Recruitment & locations

Not recruiting

Gilbert, United States · Bellflower, United States · Encino, United States

96 more locations

La Jolla, United States
Los Angeles, United States
Montclair, United States
Oakland, United States
Orange, United States
Riverside, United States
San Jose, United States
Santa Ana, United States
Stanford, United States
Thousand Oaks, United States
Upland, United States
Lauderhill, United States
Miami, United States
Miami Lakes, United States
Okeechobee, United States
Orlando, United States
Tampa, United States
West Palm Beach, United States
Atlanta, United States
Decatur, United States
Chicago, United States
Skokie, United States
Belmont, United States
Boston, United States
North Worcester, United States
Watertown, United States
Ann Arbor, United States
Eden Prairie, United States
Saint Charles, United States
Lincoln, United States
Berlin, United States
Princeton, United States
Toms River, United States
Amherst, United States
New York, United States
Staten Island, United States
The Bronx, United States
Cincinnati, United States
Cleveland, United States
Columbus, United States
Media, United States
Austin, United States
Bellaire, United States
Dallas, United States
Fort Worth, United States
Houston, United States
Plano, United States
Draper, United States
Salt Lake City, United States
Seattle, United States
Québec, Canada
Kamloops, Canada
Kelowna, Canada
Penticton, Canada
Chatham, Canada
Toronto, Canada
Vancouver, Canada
Klecany, Czechia
Kutná Hora, Czechia
Ostrava, Czechia
Pilsen, Czechia
Prague, Czechia
Aalborg, Denmark
Paris, France
Nîmes, France
Berlin, Germany
Frankfurt, Germany
Lübeck, Germany
Dublin, Ireland
Galway, Ireland
Groningen, Netherlands
Leiden, Netherlands
Utrecht, Netherlands
Bydgoszcz, Poland
Gdansk, Poland
Barcelona, Spain
Madrid, Spain
Sant Boi de Llobregat, Spain
Valladolid, Spain
Zamora, Spain
Landskrona, Sweden
Lund, Sweden
Solna, Sweden
Stockholm, Sweden
Bodmin, United Kingdom
Chertsey, United Kingdom
Chester, United Kingdom
Doncaster, United Kingdom
Exeter, United Kingdom
Fulbourn, United Kingdom
London, United Kingdom
Newcastle, United Kingdom
Nottingham, United Kingdom
Oxford, United Kingdom
Sheffield, United Kingdom
Czechia

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is COMPASS Pathways.

Does this study involve medication?

Yes. The study involves medication, including Psilocybin.

Who can participate?

This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as active, but no longer recruiting.

Want to explore more studies?

Explore studies